Novel antibody-based therapeutics have revolutionised healthcare and are a prominent feature on top-selling pharmaceutical lists. As antibody engineering and manufacturing technologies improve, previously untreatable diseases can be targeted with increased speed and efficiency. Creating a pathway that balances cost, speed and risk for therapeutic antibody development is crucial to successful and timely approval of new therapeutics.

Author: by Lonza

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center